DIVA Laboratories Ltd - Asset Resilience Ratio

Latest as of December 2025: 0.01%

DIVA Laboratories Ltd (4153) has an Asset Resilience Ratio of 0.01% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DIVA Laboratories Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

NT$70.00K

≈ $2.21K USD Cash + Short-term Investments

Total Assets

NT$1.35 Billion

≈ $42.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how DIVA Laboratories Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of DIVA Laboratories Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down DIVA Laboratories Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 4153 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	NT$0.00	0%
Short-term Investments	NT$70.00K	0.01%
Total Liquid Assets	NT$70.00K	0.01%

Asset Resilience Insights

Limited Liquidity: DIVA Laboratories Ltd maintains only 0.01% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

DIVA Laboratories Ltd Industry Peers by Asset Resilience Ratio

Compare DIVA Laboratories Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Eurofins-Cerep SA PA:ALECR	Diagnostics & Research	6.56%
Inoviq Ltd AU:IIQ	Diagnostics & Research	56.29%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Imagion Biosystems Ltd AU:IBX	Diagnostics & Research	150.16%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%

Annual Asset Resilience Ratio for DIVA Laboratories Ltd (2018–2025)

The table below shows the annual Asset Resilience Ratio data for DIVA Laboratories Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	0.01%	NT$70.00K ≈ $2.21K	NT$1.35 Billion ≈ $42.65 Million	-0.35pp
2023-12-31	0.35%	NT$4.37 Million ≈ $137.62K	NT$1.24 Billion ≈ $39.18 Million	+0.35pp
2022-12-31	0.00%	NT$7.00K ≈ $220.54	NT$1.25 Billion ≈ $39.44 Million	-0.08pp
2021-12-31	0.08%	NT$946.00K ≈ $29.80K	NT$1.18 Billion ≈ $37.23 Million	-0.41pp
2020-12-31	0.49%	NT$5.42 Million ≈ $170.63K	NT$1.11 Billion ≈ $35.07 Million	-3.66pp
2019-12-31	4.15%	NT$53.96 Million ≈ $1.70 Million	NT$1.30 Billion ≈ $41.00 Million	+4.04pp
2018-12-31	0.11%	NT$1.42 Million ≈ $44.83K	NT$1.32 Billion ≈ $41.68 Million	--

pp = percentage points

About DIVA Laboratories Ltd

TWO:4153 Taiwan Diagnostics & Research

Market Cap

$56.56 Million

NT$1.80 Billion TWD

Market Cap Rank

#21409 Global

#1311 in Taiwan

Share Price

NT$30.60

Change (1 day)

+0.16%

52-Week Range

NT$30.40 - NT$43.50

All Time High

NT$76.08